Tisagenlecleucel

Ask MedXY AI

Latest news

Tag

Hematology-Oncologyhematopoietic stem cell transplantCAR-T Therapy

Tisagenlecleucel for Post-Transplant Relapse in Young Acute Lymphoblastic Leukemia Patients: European Real-World Determinants of Outcome

By MedXY|Sep 17, 2026

This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Euro

$TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL$

Hematology-OncologyB細胞急性リンパ性白血病CAR T-cell therapy

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

By MedXY|Apr 12, 2026

A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Pa

$Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial$

Clinical UpdatesCAR T-cell therapyDiffuse large B-cell lymphoma

Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial

By MedXY|Dec 8, 2025

Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.